International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Postoperative hypofractionated proton beam therapy to control recurrent paraganglioma at the jugular foramen: A case report
Paragangliomas (PGLs) are rare neuroendocrine tumors with malignant potential that may prove challenging to manage. Those arising at the jugular foramen are particularly problematic, especially if recurring after primary surgical treatment. Long‑term follow‑up is required, and effective treatment options for such recurrences are needed. The present study chronicles a recurring PGL of the jugular foramen that emerged after two surgeries. Alternative therapeutic strategies were accordingly pursued. This account of the related clinical course includes a discussion of the associated literature, focusing on the role of proton beam therapy (PBT) in PGL management and its benefits. The patient under treatment received hypofractionated PBT, utilizing intensity‑modulated proton therapy/pencil‑beam scanning techniques. The prescribed dose was 40 Gy in 15 fractions [equivalent dose in 2‑gy fractions (EQD2), 42.09 Gy, assuming α/β=10) delivered to the gross tumor volume (GTV). Simultaneous integrated boosts to two inner subvolumes [GTV reduced by 2‑mm margin, 50 Gy/15 fractions (EQD2, 55.49 Gy); and GTV reduced by 3‑mm margin, 60 Gy/15 fractions (EQD2, 70.00 Gy)] took place as well. This process ensured precise radiation dosing, while adhering to strict dose constraints for adjacent critical structures. Hence, a quicker therapeutic response (aligned with that of stereotactic radiotherapy principles) was tenable, aiming for both tumor control and clinical improvement. Long‑term follow‑up is imperative to assess outcome durability. The aforementioned events illustrate the potential utility of advanced PBT techniques (namely pencil‑beam scanning, hypofractionated regimens) in managing PGL recurrences of this type, especially if surgical options are limited or carry substantial risks. PBT offers a precise therapeutic alternative, with tumor control capabilities that promise to preserve critical tissues near key locations at the base of the skull.